Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ESCMID Framework for Reaching Consensus in Clinical Guidelines.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

TORCH agents in women of fertile age: towards prevention of congenital infections, Italy, 2019 to 2020.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026
Same author

Lactoferrin reduces febrile neutropenia in children receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled trial.

Haematologica·2026
Same author

Guiding principles for implementing ESCMID clinical practice guidelines.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Incorporating Ethics in Clinical Guidelines in Infectious Diseases: A Scoping Review.

JAMA network open·2025
Same author

Scope and Aims of ESCMID Guidelines' - Author's reply.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2025

Related Experiment Video

Updated: Jun 6, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

Do adherence rates and glaucomatous visual field progression correlate?

Gemma C M Rossi1, Gian Maria Pasinetti, Luigia Scudeller

  • 1University Eye Clinic, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. gemma.rossi.md@gmail.com

European Journal of Ophthalmology
|December 9, 2010
PubMed
Summary

High adherence to glaucoma medication, tracked with Travatan Dosing Aid (TDA), is linked to stable visual fields. Poor adherence significantly increases the risk of vision worsening in glaucoma patients.

More Related Videos

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

Related Experiment Videos

Last Updated: Jun 6, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

Area of Science:

  • Ophthalmology
  • Glaucoma Research
  • Patient Adherence Studies

Background:

  • Glaucoma is a progressive optic neuropathy leading to irreversible vision loss.
  • Effective management of glaucoma relies heavily on consistent patient adherence to prescribed treatments.
  • The Travatan Dosing Aid (TDA) offers a method to monitor medication adherence.

Purpose of the Study:

  • To investigate the relationship between visual field progression and medication adherence in glaucoma patients.
  • To evaluate the efficacy of the Travatan Dosing Aid (TDA) in tracking adherence over 36 months.
  • To identify predictors of visual field progression, focusing on adherence rates.

Main Methods:

  • A retrospective study involving 35 patients with primary open-angle glaucoma.
  • Patients were on monotherapy with travoprost or a fixed combination of travoprost/timolol.
  • Visual field tests and adherence data from the TDA were collected over 36 months (2007-2009).
  • Statistical analyses (chi-square, Fisher exact, Mann-Whitney tests) were used to assess associations between visual field progression and adherence rates.

Main Results:

  • Patients with stable visual fields demonstrated significantly higher median adherence rates (85%) compared to those with worsening fields (21%) (p<0.001).
  • A high adherence rate (≥90%) was associated with no visual field progression.
  • Conversely, 43.5% of patients with lower adherence experienced visual field worsening (p=0.01).
  • No significant association was found between visual field progression and other factors like age, IOP, or time since diagnosis.

Conclusions:

  • Medication adherence rate plays a crucial role in the progression of glaucomatous damage.
  • Intraocular pressure (IOP) targets should be considered in conjunction with patient adherence rates.
  • Implementing strategies to improve adherence, such as monitoring tools and patient education, is essential for preserving visual function.